SHEL.UK

2,473.5

-1.67%↓

BP

368.3

-3.36%↓

SHEL.UK

2,473.5

-1.67%↓

BP

368.3

-3.36%↓

SHEL.UK

2,473.5

-1.67%↓

BP

368.3

-3.36%↓

SHEL.UK

2,473.5

-1.67%↓

BP

368.3

-3.36%↓

SHEL.UK

2,473.5

-1.67%↓

BP

368.3

-3.36%↓

Search

Smith & Nephew PLC

Fermé

1,078.5 2.08

Résumé

Variation du prix de l'action

24h

Actuel

Min

1052.5

Max

1080.5

Chiffres clés

By Trading Economics

Revenu

107M

Ventes

1.4B

P/E

Moyenne du Secteur

30.871

24.983

BPA

0.376

Rendement du dividende

2.68

Marge bénéficiaire

7.57

Employés

17,349

EBITDA

260M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+15.5% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.68%

5.79%

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

432M

9.5B

Ouverture précédente

1076.42

Clôture précédente

1078.5

Smith & Nephew PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 mai 2025, 23:40 UTC

Actions en Tendance

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 mai 2025, 23:33 UTC

Principaux Mouvements du Marché

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 mai 2025, 23:25 UTC

Principaux Mouvements du Marché

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 mai 2025, 23:25 UTC

Résultats

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mai 2025, 22:58 UTC

Résultats

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 mai 2025, 21:35 UTC

Résultats

Cisco Systems Names Patterson as CFO, Patel as President

14 mai 2025, 23:59 UTC

Market Talk

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 mai 2025, 23:49 UTC

Market Talk

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 mai 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2025, 23:48 UTC

Market Talk

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 mai 2025, 23:47 UTC

Market Talk

Gold Gains on Possible Technical Recovery -- Market Talk

14 mai 2025, 23:34 UTC

Acquisitions, Fusions, Rachats

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 mai 2025, 23:10 UTC

Résultats

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mai 2025, 23:07 UTC

Résultats

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 mai 2025, 23:00 UTC

Actualités

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 mai 2025, 22:43 UTC

Résultats

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 mai 2025, 22:34 UTC

Résultats

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 mai 2025, 22:33 UTC

Résultats

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero Did Not Declare a Dividend>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 mai 2025, 22:28 UTC

Résultats

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 mai 2025, 22:28 UTC

Résultats

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 mai 2025, 22:27 UTC

Résultats

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 mai 2025, 22:27 UTC

Résultats

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 mai 2025, 22:23 UTC

Actualités

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 mai 2025, 22:15 UTC

Résultats

Correction to Cisco Earnings Article -- WSJ

14 mai 2025, 21:48 UTC

Résultats

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 mai 2025, 21:37 UTC

Résultats

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Comparaison

Variation de prix

Smith & Nephew PLC prévision

Objectif de Prix

By TipRanks

15.5% hausse

Prévisions sur 12 Mois

Moyen 1,231.2 GBX  15.5%

Haut 1,400 GBX

Bas 1,025 GBX

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

4

Achat

6

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

$

À Propos Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.